dapagliflozin propanediol (oral): determination of ... · [email protected] m: +91 9814133808...
TRANSCRIPT
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd
DAPAGLIFLOZIN PROPANEDIOL (ORAL):
DETERMINATION OF PERMISSIBLE DAILY
EXPOSURE (PDE) AND OCCUPATIONAL
EXPOSURE LIMIT (OEL)
1
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Table of Contents
1. BASIC INFORMATION…………………………………………………...………..……3 2. HAZARDS IDENTIFIED…………………………………………………...………...….4 3. SUMMARY OF ASSESSMENT PROCESS (CALCULATIONS OF PDE VALUE)......5 4. IDENTIFIED OF THE ACTIVE SUBSTANCE…………………………………….…...8 5. OBJECTIVE AND SEARCH STRATEGY……………………………………….….......9 6. INTRODUCTION………………………………………………………………….…......97. HAZARD IDENTIFICATION……………………………………………………..……..9
a. Pharmacodynamics Data…………………………………………………………........9 b. Acute Toxicity……………………………………………………………..…...........10 c. Repeated dose toxicity…………………………………………………...……..........10 d. Carcinogenicity…………………………………………………………....................13e. In Vitro / In Vivo Genotoxicity Studies………………………………………...……13 f. Reproductive and Developmental Toxicity………………………………….............14 g. Local tolerance studies…………………………………………………………..…...16
8. IDENTIFICATION OF CRITICAL EFFECTS…………………………………….…...16 a. Most Sensitive Indicator of an Adverse Effect Seen in Clinical Toxicity Data…......16 b. Clinical Therapeutic and Adverse Effects…………………………………….…......16
9. RATIONALE FOR NOEL VALUES SELECTION ………………………………........17 10. APPLICATION OF ADJUSTMENT FACTORS (RATIONALE FOR
THE ADJUSTMENT FACTORS …………………………………………………......17 a. F1: Interspecies Differences…………………………………………………............17 b. F2: Inter-Individual Differences……………………………………………………..17 c. F3: Duration of Exposure……………………………………………………..….......18 d. F4: Nature of Toxicity………………………………………………………….........18 e. F5: Quality of Data…………………………………………………………….…….19
11. PK CORRECTION………………………………………………………………..……..20 12. REFERENCES…………………………………………………………………….…….21
ANNEXURE I: PHARMACOKINETICS AND METABOLISM ……………………….22
ANNEXURE II: Glossary………………………………………………………………........23
ANNEXURE III: Summary of Expert CV..............................................................................29
2
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd 2. HAZARDS IDENTIFIED
Yes No Unknown
Genotoxicant
Carcinogen
Reproductive and
Developmental
toxicant
Highly Sensitizing
potential
4
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd 3. SUMMARY OF ASSESSMENT PROCESS (CALCULATION OF PDE
VALUE)PDE value 0.333mg/day
OEL value 0.026 mg/m3/day
HAZARD IDENTIFICATION
Pharmacodynamics data Dapagliflozin inhibits the sodium-glucose
contransporter 2(SGLT2), the major transporter
responsible for renal glucose re-absorption which is
primarily located in the proximal tubule of the nephron.
Acute toxicity Oral LD50 was found to be 750 mg/kg in rats and 3000
mg/kg in mice, no mortality but emesis was observed in
the single-dose dog study.
Repeated dose toxicity Repeated dose toxicity studies were performed in rats,
mice and dogs. Decreased activity, abdominal distention
and hunched posture were observed at all doses in the 3-
month mouse toxicity study. In rats the target organs for
toxicity were kidney and bone. Dose related changes
were seen in dogs such as increase in urine volume,
total urine glucose, calcium and phosphorus, increase in
absolute and relative adrenal gland weight (males and
females), liver (males) and kidney (males), decreased
urine osmolality, no organ toxicity was observed even
at very high dose of dapagliflozin.
Carcinogenicity No evidence of carcinogenic potential in 2 years study
in mice and rats.
5
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Genotoxicity studies Dapagliflozin propanediol was not mutagenic or
clastogenic in an in vitro Ames assay or in the in vivo
assays. However, dapagliflozin was clastogenic in the
presence of S9 in multiple in vitro chromosomal
aberration assays. In conclusion there is no evidence for
any clinically relevant genotoxic potential of
Dapagliflozin propanediol.
Reproductive/Developmental
toxicity
Mortality and morbidity was observed in the 300/210
mg/kg high dose male rats in fertility studies. In
embryonic fetal development studies in rats 21-22 late
gestation fetal deaths were reported in 150 and 300
mg/kg dosed group along with reduction of live litter
size and decreased fetal body weights, dose-dependent
significant findings in the offspring were
malformations: in the blood vessels, fused/wavy ribs
and verterbral centra, duplicated manubira and skeletal
variations: reduced ossifications. Incidence and severity
of renal pelvic dilation was increased in the high dose
groups in rat’s prenatal and postnatal studies.
IDENTIFICATION OF CRITICAL EFFECTS
Sensitive indicator of an adverse
effect seen in non-clinical toxicity
data
Target organ toxicities at 150 mg/kg were observed in
rats in the kidney, sternum and femur, trachea, heart and
vessels, spleen and liver, harderian gland. Increase in
absolute and relative adrenal gland weight (males and
females), liver (males) and kidney (males), decreased
urine osmolality was seen in dogs. Incidence and
severity of renal pelvic dilation was increased in the
high dose groups in rat’s prenatal and postnatal studies.
6
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Clinical therapeutic and adverse
effects
FORXIGA (dapagliflozin) was studied as monotherapy
and in combination with other antidiabetic medications,
including metformin, glimepiride, or insulin.
FORXIGA was also studied in patients with type 2
diabetes and cardiovascular disease and in patients with
mild to moderate renal impairment. Adverse effect
reported in at least three (3) FORXIGA 10 mg-treated
patients were renal impairment (0.8%), decrease in
creatinine clearance (0.6%), increased blood creatinine
(0.3%), urinary tract infections (0.2%), and
vulvovaginal mycotic infection (0.1%).
NOAEL NOAEL value of 1 mg/kg is selected from the prenatal
and postnatal development studies in rats.
APPLICATION OF ADJUSTMENT FACTORS
F1: Extrapolation between species 5 For extrapolation from rats to humans.
F2: Inter-individual variability 10 Used for differences between individuals in the
human population. F3: Duration of toxicity 1 For prenatal and postnatal development studies
in rats. F4: Severe toxicity (1-10) 3 A factor of 3 (1 for embryo fetal toxicity with
maternal toxicity and 2 for systemic toxicityF5: NOAEL Vs LOAEL (10 if
LOAEL)
1 NOAEL value is selected from reproductive
toxicity studies in rats.
α (Correction for Bioavailability) 1.28 Oral is the intended route of dapagliflozin
propanediol for population. Considering worst BV ( The volume of air inhaled
during an eight-hour work shift) 10 A healthy adult human can inhale 10 m3 of air
during an eight-hour time
PK correction For PDE calculation, no Pharmacokinetic correction
was carried out, for OEL calculation a factor of 1.28
is used.
7
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd 4. IDENTITY OF THE ACTIVE SUBSTANCE:-
Dapagliflozin propanediol is a potent, competitive, reversible, highly selective and orally active
inhibitor of the human sodium-glucose co-transporter 2 (SGLT2), the major transporter
responsible for the renal glucose reabsorption.
IUPAC NAME: (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-
(hydroxymethyl)oxane-3,4,5-triol;(2S)-propane-1,2-diol;hydrate
Chemical Abstract services (CAS) Registry Number: -960404-48-2
Molecular Weight: - 502.985 g/mol
Chemical Formula: -C24H35ClO9
Chemical Description and Physical Properties:-
Dapagliflozin propanediol is a non-hygroscopic, crystalline white to off-white powder which is
soluble in polar solvents.
Figure 1: Structure of Dapagliflozin propanediol (1)
8
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd 5. OBJECTIVE AND SEARCH STRATEGY
At present, pharmaceutical companies are investing significant effort to assess and control cross-
contamination risk of drug products that are manufactured in the shared production facilities
(EMA/CHMP/ CVMP/ SWP/169430/2012) (EMA, 2014). Determination of health based
exposure limits for a residual active substance through the derivation of a safe threshold value is
employed to identify the risk posed. The derivation of threshold value like permitted daily
exposure (PDE) or thresholds of toxicological concern are used to determine the risk of the
active pharmaceutical substance. For determination of PDE, all the available pharmacological
and toxicological data including both non-clinical and clinical data should be evaluated. This
involves hazard identification by reviewing all relevant data, identification of critical effects,
determination of NOAEL of the findings that are considered to be critical effects.
In this document, brief summary of pharmacological, pharmacokinetics and toxicity data of
Dapagliflozin propanediol have been presented based on the published data. The data were
extracted from PubMed, PubChem, TOXLINE, Drugdex, RTECS (Registry of Toxic effects of
Chemical Substances), National Toxicology Program (NTP), and FDA.
6. INTRODUCTION
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes
mellitus type 2. It helps to improve glycemic control by inhibiting glucose resorption in the
proximal tubule of the nephron and causing glycosuria along with diet and exercise in adult. (2)
Dapagliflozin propanediol falls in the category of anti-diabetic drugs and the ATC code is
A10BD15 (3)
7. HAZARD IDENTIFICATIONa. Pharmacodynamics Data: -Dapagliflozin inhibits the sodium-glucose contransporter
2(SGLT2), the major transporter responsible for renal glucose re-absorption which is
primarily located in the proximal tubule of the nephron. Dapagliflozin lowers plasma glucose
by inhibiting the renal re-absorption of glucose in the proximal tubule, thereby promoting its
urinary excretion. Dapagliflozin increased renal glucose excretion in (healthy, non-diabetic)
9
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd experimental animals. This was accompanied, by osmotic diuresis as measured by increased
urine flow. (4)
b. Acute Toxicity: (4, 5)
Table No. 1: Acute toxicity studies of Dapagliflozin propanediol in laboratory animals
Route Species Dose (mg/kg) LD50
(mg/kg/day)
NOAEL
Oral Rats 375,750,
1500, 3000
750 375
Mice 375,750,
1500, 3000
3000 1500
Dogs 200, 500,
1000
- 1000
Dapagliflozin was well tolerated at doses up to 375 mg/kg in rats, 1500 mg/kg in mice, and 1000
mg/kg in dogs, no mortality but emesis was observed in the single-dose dog study.
c. Repeated dose toxicity (4, 5)
Table No. 2: Repeated dose toxicity study in mice
Route Species Strain Duration Dose(mg/kg/day) NOAEL (mg/kg/day)
Oral
gavage
Mice CD-1 1 week 4.1, 25, 43, 75 75
1month 150, 300 -
3 months 50, 150, 250, 400 150
Key Findings
• 1 week study: No drug related effect were seen in any of the dosed group
• 1 month study: one death was reported in the 150 mg/kg/day dose group but No dapagliflozin-
related pathologic changes or cause of death were determined. No death was reported in the
300 mg/kg/day group which suggested that the death at 150 mg/kg/day was not drug related.
10
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Clinical signs reported were rough/urine-stained hair coats at 150 mg/kg/day and polyuria at
150 and 300 mg/kg/day.
• 3 months’ study: The administration of dapagliflozin in the 250 and 400 mg/kg/day dose
groups was not tolerated and was associated with dapagliflozin related deaths. Decreased
activity, abdominal distention and hunched posture were observed at all doses in the 3-month
mouse toxicity study starting on Day 3. The effects generally increased with dose and are most
likely related to off target inhibition of intestinal SGLT1 and the decreased intestinal
absorption of glucose. The clinical observations in the 3-month mouse toxicity study were not
associated with decreases in body weights or food consumption. In fact, dapagliflozin-treated
mice actually exhibited increased food consumption at all doses (26 to 44%) with an increase
in end-of study body-weight gains relative to controls. Pathologic changes were limited to
decreases in absolute prostate weight (20 to 23%) at 150 and 250 mg/kg/day. The NOAEL was
considered to be 150 mg/kg/day.
Table No. 3: Repeated dose toxicity study in rats
Route Species Strain Duration Dose(mg/kg/day) NOAEL
(mg/kg/day)
Oral gavage Rats Sprague
Dawley
4 weeks 5, 50, 300 50
3 months 5, 50, 200 50
6 months 5, 25, 150 25
Key Findings
Mortality was observed at 150 mg/kg dose group but the cause of death was not determined.
There was increase in some parameter in all treatment groups such as: urinary volume, total urine
glucose, calcium and phosphorus, food consumption and water consumption, total urinary
protein. Kidney weight was increased, Serum 1, 25 dihydroxy vitamin D (males only) and
urinary deoxypyridinolene was reduced in all treatment groups. The target organs for toxicity
were kidney and bone. Kidney findings were reactive hyperplasia of collecting duct epithelium,
dilation of cortical and/or medullary tubules, and mineralisation of the collection ducts and
exacerbation of chronic progressive neuropathy (CPN). There were changes indicative of
11
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd abnormal bone formation. The mineralization and bone changes were related to increases in
serum calcium. A mechanistic study in rats on a glucose-free diet suggested that these findings
were related to off-target inhibition of intestinal SGLT1 at high doses. No changes in serum
calcium, no renal effects and no mineralisation were observed in rats on glucose-free diet. Liver
enzymes (ALT, AST) were increased with dapagliflozin in rats.
Table No. 4: Repeated dose toxicity study in dogs
Route Species Strain Duration Dose(mg/kg/day) NOAEL
(mg/kg/day)
Oral gavage Dogs Beagle 4 weeks 5, 25, 250 25
3 months 5, 30, 180 30
1 year 5, 20, 120 20
Key Findings
One female from 120 mg/kg was euthanized due to morbidity at study day 172 that was
attributed to acute renal toxicity, and one death was observed in one 5 mg/kg female due to an
aspiration pneumonia dosing accident. There was some dose related changes which included:
increase in urine volume, total urine glucose, calcium and phosphorus, increase in food
consumption and water consumption, increase in absolute and relative adrenal gland weight
(males and females), liver (males) and kidney (males), decreased urine osmolality. Minimal to
slight suburothelial inflammation was present in the renal pelvis of some dosed animals of each
group. No gross microscopy changes were observed. The increased incidence of diarrhea
following dapagliflozin administration is most likely due to the off-target inhibition of SGLT1 in
the intestines and the resulting decreases in intestinal glucose absorption. Administration of high
doses of dapagliflozin was associated with slight increases in total serum cholesterol (≤ 1.6×
relative to controls) in the 1, 3 and 12 months dapagliflozin dog studies. Increases in serum
cholesterol are most likely due to the observed increased food consumption in dogs following
dapagliflozin administration. There was no target organ toxicity observed in the repeat-dose dog
toxicity studies even at very high doses of dapagliflozin.
12
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd d. Carcinogenicity(4, 5):
Table No. 5: carcinogenic studies of Dapagliflozin propanediol
Species/route Strain Dose (mg/kg/day) Duration
Mice
Oral gavage
CD-1 M- up to 40
F- up to 20
2 years
Rats
Oral gavage
Sprague-Dawley Up to 10 2 years
The carcinogenicity studies in mice and rats were performed at large exposure multiples in
comparison to clinical exposure. No evidence of carcinogenic potential of Dapagliflozin
propanediol was seen in any of the studies.
e. In Vitro / In Vivo Genotoxicity Studies(4, 5): The following battery of tests were
performed with dapagliflozin
Table No. 6: Genotoxicity studies in vivo and in vitro.
Test system Results
In vitro Ames assay Negative
Rat bone marrow micronucleus assay Negative
Peripheral blood lymphocyte chromosomal aberration assay Negative
Hepatocyte unscheduled DNA synthesis (UDS) assay Negative
In vitro chromosomal aberration assays (in the presence of S9) Positive
In vitro chromosomal aberration assays (in the absence of S9) Negative
Dapagliflozin propanediol was not mutagenic or clastogenic in an in vitro Ames assay or in the
in vivo assays. However, dapagliflozin was clastogenic in the presence of S9 in multiple in vitro
chromosomal aberration assays. The necessity of S9 (rat liver microsomes) to elicit
13
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd clastogenicity indicates that an unidentified metabolite or metabolites of dapagliflozin were
causative, not the intact parent molecule. In conclusion there is no evidence for any clinically
relevant genotoxic potential of Dapagliflozin propanediol.
f. Reproductive and Developmental Toxicity :( 4, 5)
Fertility and early embryonic development
Table No. 7: Fertility and early embryonic development study in rats
Route Species Sex Dose (mg/kg/day) NOAEL
Oral gavage Rats M
F
M- 15, 75, 300/210
F- 3, 15, 75
NOAEL for female fertility was 15
mg/kg
NOAEL for embryonic development
was 3 mg/kg
Mortality and morbidity was observed in the 300/210 mg/kg high dose male group between
study days 4-22. In male and female rats, dapagliflozin showed no effects on mating, fertility or
early embryonic development at doses up to 75 mg/kg.
Embryonic Fetal Development
Table No. 8: Embryonic fetal development toxicity study in rats and rabbits
Route Species Sex Study type Dose
(mg/kg/day)
NOAEL
Oral
gavage
Rats F Non-GLP
study
150, 225, 300 NOAEL for embryo-fetal
development in rats was 75
mg/kg. Rats F GLP-compliant
study
37.5, 75, 150,
300
Rabbits F GLP-compliant
study
20, 60, 180 NOAEL for embryo-fetal
development in rats was 180
mg/kg.
14
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Rat study: Three out of 25 high dosed dams were found dead and one was sacrificed, some
critical signs were seen in these animals; dehydration, decreased motor activity, bradypnea,
labored breathing, gasping. Dose-dependent decreases in body weight gain were observed in all
Dapagliflozin propanediol-treated animals during the treatment period, and remained decrease in
the high dose. Total of 21 and 22 late gestation fetal deaths were reported in 150 and 300 mg/kg
dosed group along with reduction of live litter size and decreased fetal body weights. Dose-
dependent significant findings in the offspring were malformations: in the blood vessels,
fused/wavy ribs and verterbral centra, duplicated manubira and skeletal variations: reduced
ossifications were observed at 150 and 300 mg/kg. The NOAEL for maternal toxicity was not
established due to reduced food consumption and reduced body weight gain.
Rabbit study: The NOAEL for maternal toxicity was not established due to reduced food
consumption and reduced body weight gain. Litter endpoints were unaffected by Dapagliflozin
propanediol treatment, malformation and variation were not observed in the offspring.
Prenatal and postnatal development, including maternal function
Table No. 9: Prenatal and postnatal development study in rats
Species Study Clinical findings NOAEL (mg/kg)
Rats F0 Generation Body weight gain was slightly
suppressed during gestation in
high dose group.
NOAEL was not
established, 75 mg/kg was
considered LOAEL for
maternal toxicity.
F1 Generation Incidence and severity of renal
pelvic dilation was increased in
the high dose groups.
15 mg/kg
F1 Generation
Development
toxicity
Reduced weight gain during
lactation at all tested dose levels
< 1 mg/kg
F2 Generation No adverse effect were reported 75 mg/kg
15
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd g. Local tolerance studies (4)
In vitro studies with isolated bovine corneas for ocular irritation and in vivo studies with rabbits,
mice, and dogs were conducted to determine the ocular irritation, dermal irritation, sensitization
potential and vascular/perivascular irritation potential of dapagliflozin. In a Bovine Corneal
Opacity and Permeability Assay, dapagliflozin exhibited moderate to severe ocular toxicity.
Dapagliflozin was considered to be a non-sensitizer based on the results of a local lymph node
assay in the mouse. In an acute dermal irritation study in rabbits, dapagliflozin was a non-irritant.
Five days of repeated IV administration of an intravenous formulation of dapagliflozin did not
cause any vascular effects. After subcutaneous injections, there was slight focal necrosis of
subcutaneous muscle at the injection site.
8. IDENTIFICATION OF CRITICAL EFFECTS
The steps deliberated to identify the nature of the adverse effect include its severity and
persistence. If the substance causes multiple types of adverse effects, the critical effect is one that
meets the severity and persistence criteria at the lowest intake.
a. Most Sensitive Indicator of an Adverse Effect Seen in Non-Clinical Toxicity Data.
Kidney, sternum and femur, trachea, heart and vessels, spleen and liver, harderian gland were the
target organs in the rat study. In dogs, increase in absolute and relative adrenal gland weight
(males and females), liver (males) and kidney (males), decreased urine osmolality was seen.
Incidence and severity of renal pelvic dilation was increased in the high dose groups in rat’s
prenatal and postnatal studies. In embryonic fetal development studies in rats 21-22 late gestation
fetal deaths were reported in 150 and 300 mg/kg dosed groups.
b. Clinical Therapeutic and Adverse Effects
Dapagliflozin was studied as monotherapy and in combination with other antidiabetic
medications, including metformin, glimepiride, or insulin. Dapagliflozin was also studied in
patients with type 2 diabetes and cardiovascular disease and in patients with mild to moderate
renal impairment. Treatment with Dapagliflozin as monotherapy and in combination with
metformin, glimepiride, or insulin produced clinically relevant and statistically significant
improvements in mean change from baseline at Week 24 in HbA1c, fasting plasma glucose
(FPG), and 2-hour postprandial glucose (PPG) (where measured), compared to placebo or
16
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd control. The estimated, placebo-adjusted, HbA1c reduction across trials and doses ranged from
0.40% to 0.84%. These glycemic effects were sustained in long-term extensions up to 104
weeks. HbA1c reductions were seen across subgroups including gender, age, race, duration of
disease, and baseline BMI. In addition, patients treated with FORXIGA compared to placebo or
control achieved greater HbA1c reductions in patients with a baseline HbA1c ≥9% statistically
significant reductions.
Adverse effect of dapagliflozin propanediol includes female genital mycotic infections,
nasopharyngitis and urinary tract infections. frequent urination, dizziness, or lightheadedness,
UTI and kidney infection may also occur (6). The most commonly reported events leading to
discontinuation and reported in at least three (3).Dapagliflozin 10 mg-treated patients were renal
impairment (0.8%), decrease in creatinine clearance (0.6%), increased blood creatinine (0.3%),
urinary tract infections (0.2%), and vulvovaginal mycotic infection (0.1%).(6)
9. RATIONALE FOR NOAEL VALUES SELECTION
Dapagliflozin caused systemic toxicity in rats and dogs when administered for a period up to 52
weeks. Based on the relevance to clinical use, the NOAEL value of 1 mg/kg is selected from the
prenatal and postnatal development studies in rats.
10. APPLICATION OF ADJUSTMENT FACTORS (RATIONALE FOR
THE ADJUSTMENT FACTORS)
A series of modifying, or safety factors, are used when the NOAEL/ lowest therapeutic dose is
based on studies of differing types and durations in differing species to provide a risk assessment
for human exposure. These factors were generally established according to Appendices 3 of the
ICH Q3C (R5) and VICH GL 18.
a. F1: Interspecies Differences
This factor takes into account the comparative surface area: body weight ratios for the species
concerned and for man. Surface area (S) was calculated as: S= k M0.67 where M is the body mass
and the constant, k, has been taken to be 10 according to the appendices 3 of the ICH guideline.
For a 50 kg person the equation gives a surface area of 64.3 dm2; the surface area: body weight
ratio is thus 2.76.
17
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Applying the same calculation to other species and expressing the results as multiples of the
human surface area: body weight ratio gives factors for the mouse = 12; for the rat = 5; for the
monkey = 3; for the rabbit = 2.5; for the dog = 2. For other species, where the data are not so
well established the factor F1 is taken as 10.
A factor of 5 is considered as rats study is selected.
b. F2: Inter-Individual Differences
A value of F2= 10 is conventionally used to allow for differences between individuals in the
human population.
c. F3: Duration of Exposure
A variable factor up to 10 takes into account the differing durations of exposure in the reported
studies. For reproductive studies, a factor of 1 is used if the whole period of organogenesis is
covered. A factor of 1 has been used for a study last at least one-half lifetime (1 year for rodents
or rabbits; 7 years for cats, dogs and monkeys). A factor of 2 has been used for a 6-month study
in rodents, or a 3.5-year study in non-rodents. A factor of 5 has been used for a 3-month study in
rodents or a 2-year study in non-rodents and a factor of 10 for studies of a shorter duration. In all
cases, the higher factor has been used for study duration between the time points e.g. a factor of
2 for a 9-month rodent study.
A factor 1 is selected for prenatal and postnatal reproductive studies in rats.
d. F4: Nature of Toxicity
A variable factor is applied when the toxicity produced is irreversible in nature i.e.
carcinogenicity, neurotoxicity or teratogenicity. A factor of 10 is used when oncogenic or
neurotoxic responses are present. A variable factor is used for reproductive toxicity effects as
follows: 1 for embryo or foetal toxicity or mortality associated with maternal toxicity; 5 for
embryo or foetal toxicity or mortality without maternal toxicity; 5 for a teratogenic effect with
maternal toxicity and 10 for a teratogenic effect in the absence of accompanying maternal
toxicity.
A factor of 3 is used (1 for embryo fetal toxicity with maternal toxicity and 2 for systemic
toxicity observed in rats).
18
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd e. F5: Quality of Data
A variable factor, up to 1, applied to results in which a NOAEL has not been established, the
PDE being derived from a NOAEL.
As NOAEL was selected, so F5 = 1 is used in this report
The PDE calculation:
PDE value = NOAEL X Weight adjustment
F1 x F2 x F3 x F4 x F5
= 1 x 50 for adult population
5 x 10 x 1 x 3 x 1
= 0.333 mg/day
Hence, the PDE of Dapagliflozin propanediol is 0.333 mg/day
Calculation of OEL (Occupational Exposure Limits):
OEL can be calculated by using the following formula (Naumann and Weideman, 1995
and Sargent EV et al 2013)
OEL= NOAEL x BW or Human lowest daily dose
F1 x F2 x F3 x F4 x F5 x α X BLV
NOAEL value of 1 mg/kg/day was derived from the prenatal and postnatal reproductive studies
in rats and will be used for OEL generation.
OEL
= NOAELX BW F1 x F2 x F3 x F4 x F5 x BV x α
= 1x 50 5x 10 x 1 x3x 1 x10 x1.28
= 0.026 mg/m3/day
Hence, the OEL of Dapagliflozin propanediol is 0.026 mg/m3/day
19
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd 11. PK CORRECTIONFor PDE calculation, no pharmacokinetic correction was carried out, for OEL calculation a
factor of 1.28 is used.
20
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd 12. REFERENCES:
1. Dapagliflozin propanediol, Pubchem, 2019
https://pubchem.ncbi.nlm.nih.gov/compound/Dapagliflozin-propanediol
2. Dapagliflozin propanediol, Drugbank, 2019
https://www.drugbank.ca/salts/DBSALT001101
3. WHO Collaborating Centre for Drug Statistics Methodology
https://www.whocc.no/atc_ddd_index/?code=A10BD15&showdescription=yes
4. Dapagliflozin propanediol, EMA, 2012
https://www.ema.europa.eu/en/documents/assessment-report/forxiga-epar-public-assessment-
report_en.pdf
5. Dapagliflozin propanediol, FDA, 2013
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf
6. Dapagliflozin propanediol, WebMD, 2019
https://www.webmd.com/drugs/2/drug-165640/dapagliflozin-oral/details
7. Guideline on setting health based exposure limits for use in risk identification in the
manufacture of different medicinal products in shared facilities EMA/CHMP/ CVMP/
SWP/169430/2012., 2014. url:-https://www.ema.europa.eu/en/documents/scientific-
guideline/guideline-setting-health-based-exposure-limits-use-risk-identification-
manufacture-different_en.pdf
8. Guideline on setting of health-based exposure limits for use in risk identification in the
manufacture of different medicinal products in shared facilities. Date of coming into
effect in June 2015. European Medicines Agency
(EMA/CHMP/CVMP/SWP/169430/2012). URL:http://www.ema.europa.eu
9. ICH guideline Q3C (R6) on impurities: guideline for residual solvents,
EMA/CHMP/ICH/82260/2006, Access via URhttp://www.ema.europa.eu/docs
21
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd ANNEXURE I: PHARMACOKINETICS AND METABOLISM
Absorption: Following oral administration of Dapagliflozin propanediol, the maximum plasma
concentration (Cmax) is usually attained within 2 hours under fasting state. The Cmax and AUC
values increase dose proportionally with increase in Dapagliflozin propanediol dose in the
therapeutic dose range. The absolute oral bioavailability of Dapagliflozin propanediol is 78%. (2)
Distribution: Dapagliflozin propanediol is approximately 91% protein bound. Protein binding is
not altered in patients with renal or hepatic impairment.
Metabolism: The metabolism of dapagliflozin is primarily mediated by UGT1A9; CYP-
mediated metabolism is a minor clearance pathway in humans. Dapagliflozin is extensively
metabolized, primarily to yield dapagliflozin 3-O-glucuronide, which is an inactive metabolite.
Dapagliflozin 3-Oglucuronide accounted for 61% of a 50 mg [14C]-dapagliflozin dose and is the
predominant drug-related component in human plasma.
Excretion: Dapagliflozin and related metabolites are primarily eliminated via the renal pathway.
Following a single 50 mg dose of [14C]-dapagliflozin, 75% and 21% total radioactivity is
excreted in urine and feces, respectively. In urine, less than 2% of the dose is excreted as parent
drug. In feces, approximately 15% of the dose is excreted as parent drug. The mean plasma
terminal half-life (t½) for dapagliflozin is approximately 12.9 hours following a single oral dose
of 10 mg. (5)
22
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd ANNEXURE II: GLOSSARY
ADI: Acceptable daily intake
AUC: Area under the curve
GRAS: Generally regarded as safe
GLP: Good laboratory practice
GMP: Good manufacturing practice
LD: Lethal dose
LED: Lowest-effective dose
TDLo (Toxic Dose Low,): Lowest published toxic dose
LOAEL: Lowest-observed-adverse-effect level
LOEL: Lowest-observed-effect level
MSDS: Material safety data sheet
MTD: Maximum tolerable dose
MPDD: Maximum permissible daily dose
MTEL: Maximum tolerable exposure level
NEL: No-effect level
NOAEL: No-observed-adverse-effect level
NOEL: No-observed-effect level
OEL: Occupational exposure limit
QSAR: Quantitative structure–activity relationship
SDS: Safety data sheet
23
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd ADI: Acceptable daily intake. Estimate by JECFA; the amount of a food additive, expressed on a
body weight basis that can be ingested daily over a lifetime without appreciable health risk.
Area under the curve (AUC): Area between a curve and the abscissa (horizontal axis), i.e., the
area underneath the graph of a function; often, the area under the tissue (plasma) concentration
curve of a substance expressed as a function of time.
Bioaccumulation: progressive increase in the amount of a substance in an organism or part of an
organism that occurs because the rate of intake exceeds the organism’s ability to remove the
substance from the body.
Bioavailability: biological and physiological availability. Extent of absorption of a substance by
a living organism compared to a standard system.
Biological half-life: for a substance, the time required for the amount of that substance in a
biological system to be reduced to one-half of its value by biological processes, when the rate of
removal is approximately exponential.
Carcinogen: agent (chemical, physical, or biological) that is capable of increasing the incidence
of malignant neoplasms, thus causing cancer.
Clastogen: agent causing chromosome breakage and (or) consequent gain, loss, or rearrangement
of pieces of chromosomes.
Clearance: volume of blood or plasma or mass of an organ effectively cleared of a substance by
elimination (metabolism and excretion) divided by time of elimination.
Cmax: used in pharmacokinetics refering to the maximum (or peak) serum concentration that a
drug achieves in a specified compartment or test area after the drug has been administrated and
before the administration of a second dose.
Critical dose: dose of a substance at and above which adverse functional changes, reversible or
irreversible, occur in a cell or an organ.
Critical effect: for deterministic effects, the first adverse effect that appears when the threshold
(critical) concentration or dose is reached in the critical organ:
24
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Adverse effects with no defined threshold concentration are regarded as critical. Dose (of a
substance): total amount of a substance administered to, taken up, or absorbed by an organism,
organ, or tissue.
Draize test: evaluation of materials for their potential to cause dermal or ocular irritation and
corrosion following local exposure; generally using the rabbit model (almost exclusively the
New Zealand White) although other animal species have been used.
Elimination (in toxicology): disappearance of a substance from an organism or a part thereof, by
processes of metabolism, secretion, or excretion.
Embryotoxicity: production by a substance of toxic effects in progeny in the first period of
pregnancy between conception and the fetal stage.
Fetotoxicity: production by a substance of toxic effects in progeny in the second period of
pregnancy between fetal stage and delivery.
First-pass effect: biotransformation and, in some cases, elimination of a substance in the liver
after absorption from the intestine and before it reaches the systemic circulation.
Gavage: administration of materials directly into the stomach by esophageal intubation.
Generally regarded as safe (GRAS): phrase used to describe the USFDA philosophy that justifies
approval of food additives that may not meet the usual test criteria for safety but have been used
extensively and have not demonstrated that they cause any harm to consumers.
Genotoxic: capable of causing a change to the structure of the genome.
Good laboratory practice (GLP) principles: fundamental rules incorporated in OECD guidelines
and national regulations concerned with the process of effective organization and the conditions
under which laboratory studies are properly planned, performed, monitored, recorded, and
reported.
Good manufacturing practice (GMP) principles: fundamental rules incorporated in national
regulations concerned with the process of effective organization of production and ensuring
standards of defined quality at all stages of production, distribution, and marketing.
25
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Hazard identification: determination of substances of concern, their adverse effects, target
populations, and conditions of exposure, taking into account toxicity data and knowledge of
effects on human health, other organisms, and their environment.
Hypersensitivity: state in which an individual reacts with allergic effects following exposure to a
certain substance (allergen) after having been exposed previously to the same substance.
In silico: phrase applied to data generated and analyzed using computer modeling and
information technology.
In vitro: in glass, referring to a study in the laboratory usually involving isolated organ, tissue,
cell, or biochemical systems.
In vivo: In the living body, referring to a study performed on a living organism.
Lethal dose (LD): amount of a substance or physical agent (e.g., radiation) that causes death
when taken into the body.
Lowest-effective dose (LED): lowest dose of a chemical inducing a specified effect in a specified
fraction of exposed individuals.
Lowest published toxic dose (Toxic Dose Low, TDLo): the lowest dosage per unit of
bodyweight (typically stated in milligrams per kilogram) of a substance known to have produced
signs of toxicity in a particular animal species.
Lowest-observed-adverse-effect level (LOAEL): lowest concentration or amount of a substance
(dose), found by experiment or observation, that causes an adverse effect on morphology,
functional capacity, growth, development, or life span of a target organism distinguishable from
normal (control) organisms of the same species and strain under defined conditions of exposure.
Lowest-observed-effect level (LOEL): lowest concentration or amount of a substance (dose),
found by experiment or observation, that causes any alteration in morphology, functional
capacity, growth, development, or life span of target organisms distinguishable from normal
(control) organisms of the same species and strain under the same defined conditions of
exposure.
26
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd Material safety data sheet (MSDS): compilation of information required under the U.S. OSHA
Hazard Communication Standard on the identity of hazardous substances, health and physical
hazards, exposure limits, and precautions.
Maximum permissible daily dose (MPDD): maximum daily dose of substance whose penetration
into a human body during a lifetime will not cause diseases or health hazards that can be detected
by current investigation methods and will not adversely affect future generations.
Maximum tolerable dose (MTD): highest amount of a substance that, when introduced into the
body, does not kill test animals (denoted by LD0).
Maximum tolerable exposure level (MTEL): maximum amount (dose) or concentration of a
substance to which an organism can be exposed without leading to an adverse effect after
prolonged exposure time. Maximum tolerated dose (MTD): high dose used in chronic toxicity
testing that is expected on the basis of an adequate subchronic study to produce limited toxicity
when administered for the duration of the test period.
Median lethal dose (LD50): statistically derived median dose of a chemical or physical agent
(radiation) expected to kill 50 % of organisms in a given population under a defined set of
conditions.
Mutagenicity: ability of a physical, chemical, or biological agent to induce (or generate) heritable
changes (mutations) in the genotype in a cell as a consequence of alterations or loss of genes or
chromosomes (or parts thereof).
No-effect level (NEL): maximum dose (of a substance) that produces no detectable changes
under defined conditions of exposure.
No-observed-adverse-effect level (NOAEL): greatest concentration or amount of a substance,
found by experiment or observation, which causes no detectable adverse alteration of
morphology, functional capacity, growth, development, or life span of the target organism under
defined conditions of exposure. No-observed-effect level (NOEL): greatest concentration or
amount of a substance, found by experiment or observation, that causes no alterations of
morphology, functional capacity, growth, development, or life span of target organisms
27
www.indivirtus.com [email protected] M: +91 9814133808
Regd. Office: 5020-A, Sector 38 (W), Chandigarh 160014
Healthcare Services (P) Ltd distinguishable from those observed in normal (control) organisms of the same species and strain
under the same defined conditions of exposure.
Quantitative structure–activity relationship (QSAR): quantitative structure–biological activity
model derived using regression analysis and containing as parameters physicochemical
constants, indicator variables, or theoretically calculated values.
Safety data sheet (SDS): single page giving toxicological and other safety advice, usually
associated with a particular preparation, substance, or process.
Target (in biology): any organism, organ, tissue, cell or cell constituent that is subject to the
action of an agent.
Temporary acceptable daily intake: value for the acceptable daily intake proposed for guidance
when data are sufficient to conclude that use of the substance is safe over the relatively short
period of time required to generate and evaluate further safety data, but are insufficient to
conclude that use of the substance is safe over a lifetime. Note: A higher-than-normal safety
factor is used when establishing a temporary ADI and an expiration date is established by which
time appropriate data to resolve the safety issue should be available.
28